Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Active smoker, greater than or equal to 10 cigarettes per day, on average, for the past year.~* Age greater than or equal to 18 years.~* Motivated to quit smoking.~* Able to understand and to provide informed consent in English or French.~* Likely to be available for follow-up.~* Suffered an ACS, including myocardial infarction (MI) or unstable angina (UA) with significant coronary artery disease, and currently hospitalized or at discharge from current hospitalization.~MI is defined as positive Troponin T, Troponin I, or CK-MB levels and ≥ 1 of the following:~1. Ischemic symptoms (i.e. typical chest pain) for at least 20 minutes.~2. Electrocardiogram (ECG) changes indicative of ischemia (ST-segment elevation or depression).~3. Development of pathological Q waves on the ECG.~UA with significant coronary artery disease is defined as all of the following:~1. Negative Troponin T, Troponin I, or CK-MB levels;~2. Ischemic symptoms (i.e. typical chest pain) for at least 20 minutes;~3. ECG changes indicative of ischemia (ST-segment changes); and~4. At least one lesion ≥ 50% on angiogram performed during the current hospitalization.~Exclusion Criteria:~* Medical condition with a prognosis of \< 1 year.~* Pregnant or lactating females.~* Reported NYHA Class or Killip III or IV at randomization.~* Previous use of varenicline.~* Current use of any medical therapy for smoking cessation (e.g. BuSpar, doxepin,fluoxetine, nicotine gum, nicotine patch, or bupropion).~* History of bulimia or anorexia nervosa.~* Diagnosis of major depression (requiring medication) in the previous 5 years or diagnosis of two or more lifetime episodes of major depression (requiring medication)~* A total of 5 or more responses (one of which includes question 1 or 2) of more than half the days or nearly every day to the questions on the PHQ-9 questionnaire.~* History of suicidal events (previous suicide attempt, suicidal ideation) or family history of suicide.~* History of or current panic disorder, psychosis, bipolar disease, or dementia.~* Diagnosed hepatic failure, cirrhosis, hepatitis or history of hepatic impairment (AST or ALT levels greater than or equal to 2 times upper limit of normal prior to admission for ACS).~* Renal impairment with creatinine levels greater than or equal to 2 times the upper limit of normal.~* Excessive alcohol consumption defined as greater than or equal to 14 alcoholic drinks per week.~* Use of any illegal drugs in the past year (e.g. cocaine, heroin, opiates).~* Use of any marijuana or other tobacco products during the study.~* Current use of over-the-counter stimulants (e.g. ephedrine, phenylephrine) or anorectics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Varenicline (Type: EXPERIMENTAL): 0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
- Sugar pill (Type: PLACEBO_COMPARATOR): placebo for 0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).